SCHOTT Pharma AG & Co. KGaA (1SXP) - Total Assets
Based on the latest financial reports, SCHOTT Pharma AG & Co. KGaA (1SXP) holds total assets worth €1.44 Billion EUR (≈ $1.69 Billion USD) as of September 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check SCHOTT Pharma AG & Co. KGaA (1SXP) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
SCHOTT Pharma AG & Co. KGaA - Total Assets Trend (2020–2024)
This chart illustrates how SCHOTT Pharma AG & Co. KGaA's total assets have evolved over time, based on quarterly financial data. Check 1SXP operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
SCHOTT Pharma AG & Co. KGaA - Asset Composition Analysis
Current Asset Composition (June 2024)
SCHOTT Pharma AG & Co. KGaA's total assets of €1.44 Billion consist of 40.8% current assets and 59.2% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 1.6% |
| Accounts Receivable | €174.89 Million | 12.1% |
| Inventory | €140.44 Million | 9.7% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €1.12 Million | 0.1% |
| Goodwill | €29.35 Million | 2.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how SCHOTT Pharma AG & Co. KGaA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of SCHOTT Pharma AG & Co. KGaA.
Key Asset Composition Facts
- Current vs. Non-Current Assets: SCHOTT Pharma AG & Co. KGaA's current assets represent 40.8% of total assets in 2024, an increase from 40.1% in 2020.
- Cash Position: Cash and equivalents constituted 1.6% of total assets in 2024, down from 3.1% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 4.0% in 2020.
- Asset Diversification: The largest asset category is accounts receivable at 12.1% of total assets.
SCHOTT Pharma AG & Co. KGaA Competitors by Total Assets
Key competitors of SCHOTT Pharma AG & Co. KGaA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Gan & Lee Pharmaceuticals Co Ltd
SHG:603087
|
China | CN¥12.68 Billion |
|
Andon Health Co Ltd
SHE:002432
|
China | CN¥29.91 Billion |
|
Pegavision
TW:6491
|
Taiwan | NT$16.17 Billion |
|
Tarsons Products Limited
NSE:TARSONS
|
India | Rs11.64 Billion |
|
SciVision Biotech Inc
TW:1786
|
Taiwan | NT$2.67 Billion |
|
Nyxoah
BR:NYXH
|
Belgium | €93.60 Million |
|
I.Ceram SA
PA:ALICR
|
France | €3.91 Million |
|
Ansell Ltd
AU:ANN
|
Australia | AU$3.33 Billion |
SCHOTT Pharma AG & Co. KGaA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.35 | 1.33 | 1.72 |
| Quick Ratio | 1.03 | 0.94 | 1.32 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €153.12 Million | €117.19 Million | €231.50 Million |
SCHOTT Pharma AG & Co. KGaA - Advanced Valuation Insights
This section examines the relationship between SCHOTT Pharma AG & Co. KGaA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.48 |
| Latest Market Cap to Assets Ratio | 1.66 |
| Asset Growth Rate (YoY) | 17.1% |
| Total Assets | €1.44 Billion |
| Market Capitalization | $2.39 Billion USD |
Valuation Analysis
Above Book Valuation: The market values SCHOTT Pharma AG & Co. KGaA's assets above their book value (1.66x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: SCHOTT Pharma AG & Co. KGaA's assets grew by 17.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for SCHOTT Pharma AG & Co. KGaA (2020–2024)
The table below shows the annual total assets of SCHOTT Pharma AG & Co. KGaA from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-06-30 | €1.44 Billion ≈ $1.69 Billion |
+17.08% |
| 2023-06-30 | €1.23 Billion ≈ $1.44 Billion |
+2.95% |
| 2022-06-30 | €1.20 Billion ≈ $1.40 Billion |
+61.71% |
| 2021-06-30 | €739.89 Million ≈ $865.02 Million |
+24.14% |
| 2020-06-30 | €596.02 Million ≈ $696.81 Million |
-- |
About SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma AG & Co. KGaA develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharma, biotech, and life science industries worldwide. The company offers syriQ, a glass syringe for vaccines; syriQ BioPure, a glass syringe for biologics; syriQ BioPure silicone-free, a prefillable and silicone-free glass syringe for biologics; SCHOTT TOPPAC, a… Read more